These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 34948122)
1. New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors. Folk WP; Kumari A; Iwasaki T; Cassimere EK; Pyndiah S; Martin E; Homlar K; Sakamuro D Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948122 [TBL] [Abstract][Full Text] [Related]
2. Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. Folk WP; Kumari A; Iwasaki T; Pyndiah S; Johnson JC; Cassimere EK; Abdulovic-Cui AL; Sakamuro D J Biol Chem; 2019 Apr; 294(14):5700-5719. PubMed ID: 30733337 [TBL] [Abstract][Full Text] [Related]
3. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Pyndiah S; Tanida S; Ahmed KM; Cassimere EK; Choe C; Sakamuro D Sci Signal; 2011 Mar; 4(166):ra19. PubMed ID: 21447800 [TBL] [Abstract][Full Text] [Related]
4. Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G Mak JPY; Ma HT; Poon RYC Mol Cancer Ther; 2020 Jan; 19(1):123-134. PubMed ID: 31597711 [TBL] [Abstract][Full Text] [Related]
5. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912 [TBL] [Abstract][Full Text] [Related]
6. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518 [TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells. Martín-Guerrero SM; Casado P; Muñoz-Gámez JA; Carrasco MC; Navascués J; Cuadros MA; López-Giménez JF; Cutillas PR; Martín-Oliva D Exp Eye Res; 2019 Nov; 188():107790. PubMed ID: 31494107 [TBL] [Abstract][Full Text] [Related]
8. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278 [TBL] [Abstract][Full Text] [Related]
9. A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oh KS; Nam AR; Bang JH; Seo HR; Kim JM; Yoon J; Kim TY; Oh DY Oncogene; 2022 Aug; 41(32):3939-3952. PubMed ID: 35798878 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks. Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260 [TBL] [Abstract][Full Text] [Related]
11. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. Bahar E; Kim JY; Kim DC; Kim HS; Yoon H Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140 [TBL] [Abstract][Full Text] [Related]
12. [Employing DNA Damage Response Inhibitors to Enhance Chemosensitivity of Ovarian Carcinoma Cells]. Cai SY; Tang ZZ; Zeng M; Wang XJ; Lou JY; Liu C; Chen J Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 May; 47(3):316-20, 336. PubMed ID: 27468472 [TBL] [Abstract][Full Text] [Related]
13. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806 [TBL] [Abstract][Full Text] [Related]
15. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718 [TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders. Henning RJ; Bourgeois M; Harbison RD Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072 [TBL] [Abstract][Full Text] [Related]
17. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208 [TBL] [Abstract][Full Text] [Related]
18. MORC2 regulates DNA damage response through a PARP1-dependent pathway. Zhang L; Li DQ Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951 [TBL] [Abstract][Full Text] [Related]
19. PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome. Tapodi A; Bognar Z; Szabo C; Gallyas F; Sumegi B; Hocsak E Biochem Pharmacol; 2019 Apr; 162():98-108. PubMed ID: 30296409 [TBL] [Abstract][Full Text] [Related]
20. ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin. Li K; Yan H; Guo W; Tang M; Zhao X; Tong A; Peng Y; Li Q; Yuan Z Exp Cell Res; 2018 May; 366(1):24-33. PubMed ID: 29522753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]